AC Immune SA Forecasted to Earn FY2025 Earnings of $0.33 Per Share (NASDAQ:ACIU)

AC Immune SA (NASDAQ:ACIU) – Equities researchers at HC Wainwright dropped their FY2025 EPS estimates for shares of AC Immune in a note issued to investors on Wednesday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.33 per share for the year, down from their prior forecast of $0.34. The consensus estimate for AC Immune’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for AC Immune’s FY2026 earnings at $0.62 EPS, FY2027 earnings at $1.14 EPS and FY2028 earnings at $1.64 EPS.

AC Immune (NASDAQ:ACIU) last released its earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06).

Other research analysts also recently issued research reports about the stock. StockNews.com upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. BTIG Research started coverage on AC Immune in a research report on Friday, May 31st. They issued a “buy” rating and a $8.00 price objective on the stock.

AC Immune Price Performance

AC Immune stock traded down $0.16 during mid-day trading on Thursday, reaching $3.28. The stock had a trading volume of 69,310 shares, compared to its average volume of 453,476. AC Immune has a one year low of $2.20 and a one year high of $5.14. The company has a 50-day moving average price of $3.97 and a two-hundred day moving average price of $3.40. The company has a market capitalization of $324.39 million, a price-to-earnings ratio of -4.75 and a beta of 1.27.

Institutional Investors Weigh In On AC Immune

Hedge funds and other institutional investors have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of AC Immune during the second quarter valued at about $40,000. Lazard Asset Management LLC bought a new stake in AC Immune in the 1st quarter worth approximately $30,000. BNP Paribas Financial Markets raised its holdings in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares in the last quarter. Nixon Peabody Trust Co. purchased a new position in shares of AC Immune in the fourth quarter valued at $64,000. Finally, Vanguard Capital Wealth Advisors purchased a new position in shares of AC Immune in the second quarter valued at $56,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.